GlassScriptPhysician profile
Matthew S Buss
NPI 1902998594
$4,625.23
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $271 · 2021: $323 · 2022: $1,006 · 2023: $868 · 2024: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.15 | 2019-2024 | Ubrelvy, Synthroid, Vraylar |
| Novo Nordisk INC | $639.95 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $404.30 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $358.01 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $306.62 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $256.72 | 2019-2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $224.33 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.42 | 2019-2022 | |
| Allergan, INC. | $160.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.07 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $147.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.48 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.17 | 2022 | |
| Amarin Pharma, INC. | $93.11 | 2019-2022 | |
| Sanofi Pasteur INC. | $90.97 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $87.60 | 2022-2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $84.79 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Merck Sharp & Dohme LLC | $70.15 | 2019-2020 | |
| Astellas Pharma US INC | $59.36 | 2019-2020 | |
| Daiichi Sankyo INC. | $51.86 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $34.04 | 2022-2023 | Thinprep 2000 Processor, Aptima, Third Wave |
| E.R. Squibb & Sons, L.L.C. | $24.79 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.22 | 2023 | Quviviq |
| Viiv Healthcare Company | $17.22 | 2019 | |
| Exact Sciences Corporation | $16.64 | 2023 | Cologuard Collection Kit |
| Organogenesis INC. | $16.18 | 2019 | |
| Eisai INC. | $15.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2021 | |
| Radius Health, INC. | $13.34 | 2019 | |
| Genentech USA, INC. | $12.50 | 2019 | |
| Gilead Sciences, INC. | $12.21 | 2019 | |
| Cranial Technologies, INC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Buss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.